Analytical Data
-
基因名
PHLDA2
- Application
-
别名
Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene C protein Imprinted in placenta and liver protein Tumor-suppressing STF cDNA 3 protein Tumor-suppressing subchromosomal transferable fragment candidate gene 3 protein p17-Beckwith-Wiedemann region 1 C
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q53GA4
-
表达区间
1-152aa
-
分子量
44.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PHLDA2, or PHLDA2 protein, is a member of the pleckstrin homology-like domain family, implicated in various cellular processes, including apoptosis, proliferation, and differentiation. This protein is particularly interesting due to its involvement in the regulation of cell growth and death, which makes it a potential target for cancer therapy. Studies have shown that PHLDA2 expression is upregulated in several human cancers, suggesting its role as an oncogene in certain contexts. Furthermore, PHLDA2 has been linked to the modulation of the tumor microenvironment, influencing immune responses and metastasis. Despite these insights, the precise mechanisms by which PHLDA2 exerts its effects at the molecular level remain poorly understood. Research on the recombinant form of PHLDA2 allows scientists to investigate its structure and function in detail, enabling the identification of potential interaction partners and downstream signaling pathways. This work not only enhances our understanding of the protein's biological roles but also opens avenues for developing novel therapeutic strategies that target PHLDA2-related pathways in cancer and other diseases. Given the increasing evidence of its clinical relevance, exploring PHLDA2 as a biomarker for diagnosis or prognosis in malignancies further underscores the significance of research in this area.
